BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. (BYSI) Amendment No. 4 reports that, as of September 30, 2026, Xiangmin Cui beneficially owned 3,065,702 ordinary shares, or 7.5%, with shared voting and dispositive power. The reported holdings include 1,617,409 shares held directly by Decheng Capital China Life Sciences USD Fund II, L.P. (3.9%) and 1,448,293 shares held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (3.5%). Cui is the sole manager of both funds’ general partners and shares voting and investment authority over the funds’ shares. The reporting persons expressly disclaim group status.
BeyondSpring Inc. reported shareholder-vote totals of 20,810,814 for, 65,954 against and 29,153 abstentions.
BeyondSpring Inc. (BYSI) completed the sale of all its ownership interests in BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026, transferring indirect interests in Bulin and the SEED disposal group. The investor paid no cash consideration to BeyondSpring at closing; the noncash consideration includes a license to China-generated DUBLIN-4 data and the investor’s commitment to fund Bulin’s trial conduct and data generation.
The license is exclusive, irrevocable, perpetual, transferable, sublicensable, fully paid-up and royalty-free, but excludes use of the data for sales of Plinabulin or the combination product in mainland China, Hong Kong, Macao and Taiwan. BeyondSpring retained SEED interests representing approximately 29% of SEED’s voting power on an as-converted basis and the right to elect two Series A-1 directors, but no longer controls SEED or the sold BeyondSpring Ltd. group. During the three years after closing, Bulin must use commercially reasonable efforts to meet enrollment targets; if the shortfall is 90% or greater, the investor must return 100% of the equity interests acquired. A preliminary pro forma schedule lists a $53.677 million gain on disposition, which relates to discontinued operations; contingent consideration is excluded from the pro forma information.
BeyondSpring Inc. received notice that its market value of listed securities had remained below Nasdaq’s $35 million continued-listing threshold for 30 consecutive business days. The notice does not immediately delist the company’s securities or affect their Nasdaq trading. BeyondSpring has until March 29, 2027, to regain compliance, and its securities will continue to trade during the 180-calendar-day compliance period.
To regain compliance, the company’s market value of listed securities must close at $35 million or more for at least 10 consecutive business days before March 29, 2027; Nasdaq staff may extend that period. If BeyondSpring does not regain compliance by the deadline, Nasdaq will notify the company that its securities are subject to delisting, and the company may appeal. BeyondSpring said the notice does not affect its business operations and that it is considering available options, while noting it cannot assure that it will regain compliance or meet other Nasdaq listing criteria.
BeyondSpring Inc. (BYSI) entered an at-the-market sales agreement under which it may offer and sell up to 9,200,000 ordinary shares. Citizens JMP Securities is the sales agent and/or principal and is entitled to a commission of up to 3.0% of gross proceeds from shares sold.
BeyondSpring also agreed to sell its wholly owned subsidiary BeyondSpring Ltd. to Biolin for non-cash consideration tied to Biolin’s commitment to support the China portion of DUBLIN-4; no cash is payable at closing. Bulin must use commercially reasonable efforts to meet a BeyondSpring-set enrollment target within three years after closing. If Bulin misses the target by the end of that period, Biolin must transfer a proportional portion of the equity back; a shortfall of 90% or more requires return of all equity. Closing is subject to customary conditions, and no regulatory approval is required.
BeyondSpring receives a license to China-trial data and a right of reference in data related to Plinabulin plus docetaxel, and says it will retain global rights outside Greater China. The FDA granted Fast Track designation for Plinabulin plus docetaxel for post-ICI advanced or metastatic non-squamous NSCLC. DUBLIN-4 plans approximately 442 patients, with approximately 221 expected in China, and a prespecified interim analysis at 221 PFS events.
BeyondSpring Inc. may offer and sell up to 9,200,000 ordinary shares through Citizens JMP Securities, LLC as agent in an at-the-market offering, with an aggregate offering-price limit of $11,942,800 under current public-float restrictions. At the assumed price of $0.7772 per share, BeyondSpring estimates gross proceeds of approximately $7.15 million; Citizens may receive a commission of up to 3.0%. Net proceeds are intended for research and development and general corporate purposes.
On September 28, 2026, BeyondSpring agreed, subject to the agreement’s terms and conditions, to transfer its wholly owned BeyondSpring Ltd. to Biolin Investment Limited. As consideration, the investor is to conduct and complete the China portion of DUBLIN-4; BeyondSpring will receive related data, and its indirect SEED Therapeutics stake will be reduced. Separately, Nasdaq gave BeyondSpring until March 16, 2027, to regain compliance with the $1.00 minimum closing bid-price requirement by meeting it for at least 10 consecutive business days, after 30 consecutive business days below the threshold. The notice had no immediate effect on the listing.
BeyondSpring Inc. (BYSI) reported that on September 17, 2026 it received a notice from the Nasdaq Listing Qualifications Department that its ordinary shares no longer meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
The notice does not immediately delist the shares, and trading on Nasdaq continues. BeyondSpring has 180 calendar days, until March 16, 2027, to regain compliance. Compliance will be restored if the closing bid price is at or above $1.00 for at least 10 consecutive business days. The company may qualify for an additional 180-day period but states there is no assurance it will regain or maintain compliance.
BeyondSpring Inc. (BYSI) is calling its 2026 Annual General Meeting of Shareholders for October 13, 2026 at 9 a.m. Eastern Time in Florham Park, New Jersey, with virtual participation and voting available. Holders of ordinary shares at the close of business on August 24, 2026 may vote, with each share entitled to one vote and a quorum requiring at least a majority of the paid up voting share capital present in person or by proxy.
The sole proposal is ratification of the Audit Committee’s selection of CBIZ as independent registered public accounting firm for the fiscal year ending December 31, 2026, which the board unanimously recommends shareholders approve by simple majority of votes cast. The proxy materials are being distributed primarily via Internet access, with paper or email copies available on request, and Internet voting closes at 11:59 p.m. Eastern Time on October 12, 2026.
BeyondSpring Inc. major shareholders Ever Regal Group, Fairy Eagle Investments, Rosy Time Holdings, Lan Huang and Linqing Jia report their updated ownership of the company’s Ordinary Shares. The disclosure is an amendment to a prior Schedule 13G group filing.
Lan Huang and Linqing Jia each report 5,293,444 Ordinary Shares beneficially owned, representing 12.9% of BeyondSpring’s 41,119,820 Ordinary Shares outstanding as of June 30, 2026. Their holdings are aggregated through British Virgin Islands entities, GRATs, irrevocable trusts for Dr. Huang’s children, and shares held by unaffiliated third parties over which they have been granted voting proxies.
Ever Regal, Fairy Eagle, and Rosy Time each hold 2, 1, and 1 Ordinary Shares, respectively, reflecting 0.00% of the class. On June 19, 2026, Dr. Huang ceased serving on the board of Sincere Efforts Foundation Inc., after which neither Dr. Huang nor Mr. Jia is deemed to share voting or dispositive power over Ordinary Shares held by that entity.